{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04036045",
            "orgStudyIdInfo": {
                "id": "18-137"
            },
            "organization": {
                "fullName": "Connecticut Children's Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity",
            "officialTitle": "Integrated Basis and Translational Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "approaches-to-identify-early-biomarkers-and-pathogenesis-of-anthracycline-cardiotoxicity"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-07-25",
            "studyFirstSubmitQcDate": "2019-07-25",
            "studyFirstPostDateStruct": {
                "date": "2019-07-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Olga Salazar",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Connecticut Children's Medical Center"
            },
            "leadSponsor": {
                "name": "Connecticut Children's Medical Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Nationwide Children's Hospital",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Early microRNAs (miRs) and Cardiac Magnetic Resonance (CMR)-derived strain analysis and detection of genes contributing to Anthracycline-Induced Cardiotoxicity (AIC) sensitivity and resistance will identify pediatric cancer patients most and least likely to develop AIC.",
            "detailedDescription": "Plan is to enroll 110 children and adults (\u22659 years old) newly diagnosed at CCMC and Nationwide Children's Hospital (55 per institution) who will receive anthracyclines as part of their chemotherapy regimen.\n\nThe duration of study participation will be approximately a year.\n\nPatients will have a total of four study visits:\n\nBaseline\n\n1 week after patient's anthracycline cumulative dose hits between 60 and 100 mg/m2 After the patient has completed maximal therapy One year after completion of anthracycline treatments\n\nStudy tasks for all four visits will be:\n\nCollection of clinical data Blood draw for micro RNA and Biomarkers Cardiac MRI Echocardiogram One time blood draw for genetics"
        },
        "conditionsModule": {
            "conditions": [
                "Childhood Cancer"
            ],
            "keywords": [
                "Anthracycline induced cardiotoxicity"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_ONLY",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "pending"
            },
            "enrollmentInfo": {
                "count": 110,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Cardiac MRI",
                    "description": "Patients will have a cardiac MRI at four time points during the study",
                    "otherNames": [
                        "cMRI"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Echocardiogram",
                    "description": "Patients will have an echocardiogram at four time points during the study",
                    "otherNames": [
                        "Echo"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Blood Draw",
                    "description": "Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "CMR",
                    "description": "1. Increased myocardial T2 relaxation time in the myocardium compared to baseline as measured by T2 mapping technique",
                    "timeFrame": "From Baseline to one year after anthracycline therapy"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age (\u2265 9years old)\n* Newly diagnosed with a malignancy that will receive ACs as part of their chemotherapy.\n* Parental/caregiver consent and subject assent to enrollment.\n\nExclusion Criteria:\n\n* Subject has contraindications to CMR.\\*\n* Subject requiring sedation for CMR\n* Subject too large to be safely accommodated by CMR\n* Pregnancy tests are done routinely prior to chemotherapy, if test is positive the patient will be excluded\n* Subject's serum creatinine above guidelines for adequate renal function. See table below:\n\nAge (years) Male Female 6-10 1.0 mg/dL 1.0 mg/dL 10-13 1.2 mg/dL 1.2 mg/dL 13-16 1.5 mg/dL 1.4 mg/dL \\>16 1.7 mg/dL 1.4 mg/dL",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "9 Years",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ],
            "studyPopulation": "Patients who are \\> or equal to 9 years of age who are newly diagnosed with cancer who will receive anthracycline (s) as part of the their treatment regimen.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Olga Salazar, MD",
                    "role": "CONTACT",
                    "phone": "860-545-9400",
                    "email": "Otoro@connecticutchildrens.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Olga Salazar, MD",
                    "affiliation": "Connecticut Children's Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Olga Salazar",
                    "city": "Hartford",
                    "state": "Connecticut",
                    "zip": "06106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Olga Salazar, MD",
                            "role": "CONTACT",
                            "phone": "860-545-9410",
                            "email": "otoro@connecticutchildrens.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.76371,
                        "lon": -72.68509
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED",
            "description": "Pending"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000066126",
                    "term": "Cardiotoxicity"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000064420",
                    "term": "Drug-Related Side Effects and Adverse Reactions"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000011832",
                    "term": "Radiation Injuries"
                },
                {
                    "id": "D000014947",
                    "term": "Wounds and Injuries"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M30670",
                    "name": "Cardiotoxicity",
                    "asFound": "Cardiotoxicity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M30303",
                    "name": "Drug-Related Side Effects and Adverse Reactions",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14679",
                    "name": "Radiation Injuries",
                    "relevance": "LOW"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}